Disclosed is a compound selected from N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) 2-methylbutyric acid. Also disclosed is a method of making the crystalline forms, pharmaceutical compositions and kits comprising the crystalline forms and the use of the crystalline forms for the manufacture of a medicament for the for treating or lessening the severity of a disease in a patient, wherein said disease is selected from cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, lipid processing deficiencies, lysosomal storage diseases, neurodegenerative diseases, polyglutamine neurological disorders, spongiform encephalopathies, COPD, dry-eye disease, and Sjogren&rsquos disease .
